The Epstein-Barr virus and a high-risk gene may work together to trick the immune system into attacking the brain in MS, a ...
ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient population Patients treated with ELI-002 7P ...
Determining the specificity of HLA antibodies is arguably one of the most important contributions by the HLA laboratory today. For patients that have low-to-moderate levels of antibody, using a ...
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...
How can TCR-based therapeutics address the current limitations of treating solid tumors? The TCR increases the number and types of proteins available to surveilling T cells. Unlike a CAR, which only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback